Ghali Azza Abass, Yousef Mohamed Khalil, Ragab Osama AbdAllah, ElZamarany Enas Arafa
Neuropsychiatry, Tanta University , Tanta , Egypt.
Clinical Pathology, Tanta University , Tanta , Egypt.
Front Neurol. 2016 Dec 16;7:228. doi: 10.3389/fneur.2016.00228. eCollection 2016.
Based on many preclinical and small clinical trials, stem cells can help stroke patient with the possibility of replacing the cells and supporting the remaining cells. The aim of this study was to evaluate the safety and feasibility of bone marrow mononuclear (BMMN) stem cell transplantation in subacute ischemic stroke patients.
Thirty-nine ( = 39) patients with subacute ischemic cerebral infarct due to large artery occlusion in the middle cerebral artery (MCA) territory were recruited. They were distributed into two groups: first group ( = 21) served as an experimental group, which received intra-arterial (IA) mononuclear stem cells (bone marrow-derived mononuclear cell), while the other group ( = 18) served as a control group. All the patients were evaluated clinically by National Institutes of Health Stroke Scale, modified Rankin Scale, Barthel Index, modified and standardized Arabic version of the Comprehensive Aphasia Test, and radiological for 12 months.
The stem cell-treated group showed better improvement, but it was not significant when compared with the non-treated group. The volume of infarction changes at the end of the study was non-significant between both the groups. There was no, or minimal, adverse reactions in stem cell-treated group.
The study results suggest that autologous BMMN stem cell IA transplantation in subacute MCA ischemic stroke patients is safe with very minimal hazards, but no significant improvement of motor, language disturbance, or infarction volume was detected in stem cell-treated group compared with the non-treated group.
基于众多临床前和小型临床试验，干细胞有望通过替代细胞和支持剩余细胞来帮助中风患者。本研究旨在评估骨髓单个核（BMMN）干细胞移植在亚急性缺血性中风患者中的安全性和可行性。
招募了39例大脑中动脉（MCA）区域因大动脉闭塞导致亚急性缺血性脑梗死的患者。他们被分为两组：第一组（n = 21）作为实验组，接受动脉内（IA）单个核干细胞（骨髓来源的单个核细胞）治疗，而另一组（n = 18）作为对照组。所有患者均通过美国国立卫生研究院卒中量表、改良Rankin量表、Barthel指数、改良和标准化阿拉伯语版综合失语症测试进行临床评估，并进行为期12个月的影像学评估。
干细胞治疗组显示出更好的改善，但与未治疗组相比差异不显著。两组在研究结束时梗死体积的变化无显著差异。干细胞治疗组没有或仅有极少的不良反应。
研究结果表明，亚急性MCA缺血性中风患者自体BMMN干细胞IA移植安全性极高、风险极小，但与未治疗组相比，干细胞治疗组在运动、语言障碍或梗死体积方面未发现显著改善。
